Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.

Expert review of molecular diagnostics - 1 Oct 2016

Buonerba Carlo, Di Lorenzo Giuseppe, Sonpavde Guru

Abstract excerpt

INTRODUCTION: Currently, clinical factors related to the malignancy and patient-related factors such as performance status and comorbidities are employed to select agents to treat metastatic castration resistant prostate cancer (mCRPC). Areas covered: This paper covers emerging molecular panels that may be used in the clinic as prognostic or predictive biomarkers to treat mCRPC. Expert commentary: The expression...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Clinical Decision-Making

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Amplification

Share to Gene Expression Regulation, Neoplastic

Share to Molecular Diagnostic Techniques

Share to Neuroendocrine Tumors

Share to Prostatic Neoplasms, Castration-Resistant

Share to Receptors, Androgen

Source

Identifiers

PMID: 27665838
DOI: 10.1080/14737159.2016.1240031

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Contemporary molecular tests for prognosis and treatment guidance for castration-resistant prostate cancer.PMID 27665838Read ↗

Emerging Molecular Biomarkers in Advanced Prostate Cancer: Translation to the Clinic.Semantic proximity Read ↗

A comprehensive review of genomic landscape, biomarkers and treatment sequencing in castration-resistant prostate cancerSemantic proximity Read ↗

Molecular landscape of prostate cancer: Implications for current clinical trialsSemantic proximity Read ↗

CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Semantic proximity Read ↗

Emerging Biomarker-Guided Therapies in Prostate CancerSemantic proximity Read ↗

Genetic testing for the clinician in prostate cancer.Semantic proximity Read ↗

Homologous Recombination Repair Gene Mutations in Prostate Cancer: Prevalence and Clinical Value.Semantic proximity Read ↗

PARP inhibitors for prostate cancerSemantic proximity Read ↗

Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate CancerSemantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving toward a Personalized Treatment?Semantic proximity Read ↗

De Novo Metastatic Prostate Cancer: Are We Moving towards a Personalized Treatment?Semantic proximity Read ↗

Treatment strategies for DNA repair-deficient prostate cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.